MAM
Kapture CX names Devika Rajeev as HR head to power growth & culture
MUMBAI: The gen AI-powered customer experience platform has appointed Devika Rajeev as its new head of HR, bringing in a wealth of experience to supercharge its workforce and fuel its ambitious growth plans.
With 13 years of HR mastery under her belt, Devika isn’t just any hire—she’s a force to be reckoned with. From scaling teams at rocket-speed to crafting high-impact people strategies, she has done it all. At Sattva Consulting, she was the mastermind behind tripling the organisation’s headcount while implementing game-changing HR initiatives. Before that, she sharpened her expertise at Wipro, Heidrick & Struggles, and Ola, managing diverse teams and shaping people-first cultures.
An alumna of XLRI Jamshedpur, Devika holds a postgraduate diploma in personnel management & industrial relations and a B.A. (Hons) in mathematics from Delhi University. Now, at Kapture CX, she steps into a crucial role—one that requires equal parts strategy, agility, and a knack for making workplaces thrive.
In her new role, Devika will lead strategic HR initiatives, talent acquisition, and retention while strengthening employee engagement. Her mission? To build a dynamic and inclusive work environment that aligns with Kapture CX’s rapid expansion. With her leadership, expect a culture that champions collaboration, innovation, and continuous growth.
Kapture CX CEO & co-founder Sheshgiri Kamath welcomed her aboard with enthusiasm, “At Kapture, we believe that people are at the heart of everything we do. Devika’s extensive experience in HR leadership, combined with her ability to drive strategic talent initiatives, makes her a valuable addition to our team. We look forward to her contributions in building a strong, people-first culture as we continue our growth journey.”
Devika, equally excited about the challenge ahead, shared her thoughts, “I am thrilled to join Kapture CX at such an exciting phase of its journey. The company’s commitment to innovation and customer-centricity is truly inspiring, and I look forward to strengthening our HR strategies to nurture talent, foster a high-performance culture, and support the organisation’s ambitious goals.”
With Kapture CX continuing its march towards redefining customer experience, Devika’s appointment marks a strategic shift in how the company plans to invest in its people.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
